Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 42-year-old woman is evaluated in the clinic for severe, seropositive rheumatoid arthritis that remains highly active despite six months of maximally tolerated methotrexate and folic acid therapy. The physician plans to add adalimumab to her current regimen. She has a past medical history of mild intermittent asthma. Current medications include methotrexate, folic acid, and an as-needed albuterol inhaler. Vital signs are within normal limits. Physical examination reveals active synovitis with swelling and tenderness in the bilateral metacarpophalangeal and proximal interphalangeal joints. Which of the following baseline and ongoing monitoring parameters are required for this patient's new pharmacological regimen? (Select 3)

  1. Baseline interferon-gamma release assay (IGRA) or tuberculin skin testCevap
  2. Baseline screening for hepatitis B surface antigen and core antibodyCevap
  3. Periodic evaluation of complete blood count, serum creatinine, and liver transaminasesCevap
  4. D
    Baseline transthoracic echocardiogram to evaluate left ventricular ejection fraction
  5. E
    Routine periodic screening for antinuclear antibodies (ANA) and anti-double-stranded DNA antibodies

Cevap

The required monitoring parameters include baseline tuberculosis screening (IGRA or TST), baseline hepatitis B serologic screening, and periodic monitoring of CBC, renal function, and liver transaminases.
The correct parameters encompass the mandatory baseline infectious disease screening for TNF-alpha inhibitors and the standard ongoing toxicity monitoring for methotrexate. Adalimumab, like all TNF-alpha inhibitors, disrupts granuloma formation and macrophage function, carrying a black box warning for the reactivation of latent tuberculosis and hepatitis B. Therefore, screening with an interferon-gamma release assay (or tuberculin skin test) and hepatitis B serologies (HBsAg, anti-HBc) is universally required before initiation. Concurrently, the patient is continuing methotrexate, which inhibits dihydrofolate reductase and can cause myelosuppression, hepatotoxicity, and renal impairment. Clinical guidelines mandate periodic monitoring of complete blood count, liver transaminases, and serum creatinine to detect early, asymptomatic organ toxicity.

Adım Adım Çözüm

1
Identify the proposed pharmacological regimen and associated high-yield toxicities.
The patient will be taking methotrexate (risk of myelosuppression, hepatotoxicity, renal dysfunction) and adalimumab, a TNF-alpha inhibitor (risk of opportunistic infections, particularly granulomatous and viral).
Recognizing the specific adverse effect profiles of these disease-modifying antirheumatic drugs (DMARDs) dictates the monitoring strategy.
2
Determine the baseline screening requirements for initiating a TNF-alpha inhibitor.
Baseline screening for latent tuberculosis (via IGRA or TST) and hepatitis B (HBsAg and anti-HBc) must be performed.
TNF-alpha is essential for macrophage function and granuloma maintenance. Inhibition can lead to rapid, disseminated reactivation of latent TB and severe reactivation of hepatitis B.
3
Determine the ongoing laboratory monitoring requirements for methotrexate.
Routine periodic evaluation of complete blood count, serum creatinine, and liver transaminases is required.
Methotrexate is an antimetabolite that can cause dose-dependent toxicities requiring routine surveillance to ensure safety and allow for dose adjustments.
4
Evaluate the necessity of cardiac or autoimmune screening based on the medication profile.
Baseline echocardiography and routine ANA screening are not indicated for this asymptomatic patient.
While TNF inhibitors are contraindicated in severe heart failure and can rarely cause drug-induced lupus, clinical guidelines do not support routine baseline echocardiograms or serial autoantibody screening in asymptomatic individuals without a suggestive history.

Anahtar Kavram

Prior to initiating TNF-alpha inhibitors, patients must be screened for latent tuberculosis and hepatitis B. Patients on methotrexate require ongoing monitoring of complete blood count, liver transaminases, and renal function.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru